Press Releases Ypsomed Group

Burgdorf – Ypsomed (SIX: YPSN) is building a new production hall in Schwerin and creating 60 new jobs in the process. The company held the groundbreaking ceremony last Friday thus signaling the start of the construction for the 3300 square meters of additional production space, plus a further 1600 square meters for warehouse capacity and logistics. Digging work is scheduled to begin in June. The plant is expected to be operational following a construction phase of one year. The expansion will allow Ypsomed's site in Schwerin to produce more than 250 million infusion sets, pens and autoinjectors per year going forward.

Topics:
Access & Expansion

Press Releases Ypsomed Group

Burgdorf – On 25 April 2023, the groundbreaking ceremony for Ypsomed's (SIX: YPSN) new production facility took place in the Changzhou National Hi-tech District. In order to be able to efficiently serve the rapidly growing Chinese market for injection systems, Ypsomed is investing over CHF 35 million in the new manufacturing plant in a first phase. Production is expected to commence in the second half of 2024.

Topics:
Access & Expansion

Sébastien Delarive to become new Senior Vice President Diabetes Care
Sébastien Delarive to become new Senior Vice President Diabetes Care.

Press Releases Ypsomed Group

Burgdorf – With the aim of focusing on changing customer needs, Ypsomed is stepwise optimizing the organisation of the business units and the Management Board.

Topics:
Access & Expansion

Ypsomed continues to invest in growth

Press Releases Ypsomed Group

Burgdorf – Ypsomed (SWX: YPSN) increased its consolidated sales by CHF 9.4 million to CHF 403.7 million in the financial year 2020/21 (prior year: CHF 394.3 million). The two business segments developed differently during the Corona pandemic: while the business with pens and autoinjectors was encouraging, the sales of insulin pumps remained at a low level. Ypsomed has set an important course in the financial year 2020/21 to improve the sales opportunities for YpsoPump. The increased importance of self-treatment of chronic diseases has reinforced the company’s growth strategy. Ypsomed has therefore advanced all strategic initiatives and further improved its own competitive position. The company invested a total of CHF 142.7 million for this purpose while at the same time creating 110 new jobs. To expand financial flexibility for the future, the Board of Directors will propose an authorised increase in capital at the Annual General Meeting.

Topics:
Access & Expansion